Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

First Posted Date
2016-06-13
Last Posted Date
2024-07-31
Lead Sponsor
AIDS Malignancy Consortium
Target Recruit Count
11
Registration Number
NCT02797470
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

First Posted Date
2016-06-06
Last Posted Date
2024-10-09
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
170
Registration Number
NCT02790515
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

First Posted Date
2016-05-26
Last Posted Date
2020-03-19
Lead Sponsor
Samsung Medical Center
Target Recruit Count
25
Registration Number
NCT02784054
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

First Posted Date
2016-05-26
Last Posted Date
2018-09-18
Lead Sponsor
Samsung Medical Center
Target Recruit Count
41
Registration Number
NCT02784015
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

First Posted Date
2016-05-23
Last Posted Date
2022-11-04
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
22
Registration Number
NCT02780609
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma

First Posted Date
2016-05-16
Last Posted Date
2020-01-18
Lead Sponsor
Basque Health Service
Target Recruit Count
24
Registration Number
NCT02773550
Locations
🇪🇸

Araba of University Hospital, Vitoria-Gasteiz, Araba, Spain

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

First Posted Date
2016-05-13
Last Posted Date
2023-09-28
Lead Sponsor
Northside Hospital, Inc.
Target Recruit Count
20
Registration Number
NCT02771197
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

🇺🇸

Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

First Posted Date
2016-05-09
Last Posted Date
2024-04-17
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
138
Registration Number
NCT02766465
Locations
🇺🇸

Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Boston University, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States

and more 32 locations

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

First Posted Date
2016-04-29
Last Posted Date
2021-11-08
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT02756572
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

First Posted Date
2016-04-25
Last Posted Date
2020-10-20
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
5
Registration Number
NCT02750254
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy